Other relevant news · Mind Medicine Australia
Mind Medicine Australia logo Menu

Other relevant news

The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.

The New York Times, 09 May, 2021

Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.

Read the PDF here.

Read more

Legalise 'magic mushrooms' to help cure depression, says London scientist

My London, 06 May, 2021

The director of a pioneering psychedelic research centre on the benefits and limitations of psychedelics for depression.

Read more

A Psychedelic Drug Passes a Big Test for PTSD Treatment

The New York Times, 03 May, 2021

A new study shows that MDMA can bring relief when paired with talk therapy to those with severe post-traumatic stress disorder.

Read the PDF version here.

Read more

MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results for Patients with Severe, Chronic PTSD

Maps.org, 03 May, 2021

The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.

Read more

There Is a Lot of Fungus Among Us

The New York Times, 24 April, 2021

Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention.

Read more

Massachusetts General Hospital Launches Center to Study Neuroscience of Psychedelics

The Crimson, 23 April, 2021

Massachusetts General Hospital, an affiliate of Harvard Medical School, launched a new center to study the clinical benefits of psychedelics in treating mental illness.

Read more

Psychedelics are transforming the way we understand depression and its treatment

The Guardian, 20 April, 2021

Psychiatry has long failed to explain depression. Our research into psilocybin suggests a new approach could offer answers.

Read more

Psilocybin least as good as antidepressant in UK study

Reuters, 15 April, 2021

A study published in the New England Journal of Medicine, psilocybin could be as effective as a leading antidepressant—and while more research is still required, the study’s lead author says the results should give people hope for functional alternatives to SSRIs.

Read more

New $6.4M research program to advance psychedelics research and treatments

Eurek Alert, 30 March, 2021

Psychedelics research in support of brain health is getting a major boost this month with the formation of the Neuroscape Psychedelics Division at the University of California, San Francisco (UCSF).

Read more

Suing the DEA for Access to Psilocybin

Mushroom Revival, 24 March, 2021

A Seattle based doctor, Dr. Sunil Aggarwal, has filed a lawsuit against the DEA for denying him permission to use psilocybin therapy in his palliative care.

Read more

Psychedelic for meth users: Sydney trial aims to conquer addiction

Sydney Morning Herald, 22 March, 2021

A world-first clinical trial in Sydney aims to find out if giving psychedelics to people who use methamphetamines can help conquer their addiction.

Researchers at St Vincent’s Hospital in Darlinghurst will use psilocybin to turbocharge therapy for patients dependent on “meth” or “ice”.

Read more

Can Magic Mushrooms Heal Us?

The New York Times, 18 March, 2021

A very promising mental health experiment is taking shape in Oregon.

Read more

‘Better treatments’: Government to fund psychedelic drugs trials to treat mental illness

Sydney Morning Herald, 17 March, 2021

Clinical trials using magic mushrooms, ecstasy and other psychedelic drugs in potential breakthrough therapies for debilitating mental illnesses will be funded by the Australian federal government as part of global efforts to advance innovative treatments. The Morrison government launched a $15 million competitive grant round to kick-start Australian clinical trials of potential breakthrough combination therapies.

Read the PDF article here.

Read more

Psychedelic therapy could 'reset' depressed brain

BBC News, 16 March, 2021

A powerful hallucinogenic medicine known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time.

Read more

New Legion Veterans Village in Surrey will include centre to research medical psychedelics

Small Caps, 13 March, 2021

Surrey will soon be home to a research centre that brings together experts in medical cannabis and psychedelics to help people with post-traumatic stress disorder.

Read more

Creso Pharma Acquisition of Psychedelic Company Halucenex Life Sciences Inc.

Vancouver Sun, 15 March, 2021

Creso Pharma (ASX: CPH) has announced a transformational move to evolve from a medical cannabis company to an integrated natural medicines provider with the acquisition of Canadian psychedelics company, Halucenex Life Sciences Inc.

Read more

How psilocybin eased my cancer suffering

Herald Sun, 09 March, 2021

Read the PDF article here.

Read more

Suicide warning over denied drugs

The Australian, 09 March, 2021

Delaying mental practitioners access to psilocybin and MDMA could result in a spike in suicides amid an ongoing national mental health crisis, according to advocates for psychedelic-assisted therapy.

Read the PDF here.

Read more

Greens MP hopes Canberra will be the first to introduce psychedelic assisted therapy

The Canberra Times, 07 March, 2021

ACT Greens’ MLA Johnathan Davis wants Canberra to be the first jurisdiction to provide an accessible path for psychiatrists to prescribe psychedelic-assisted therapy to patients experiencing serious mental concerns.

Read the PDF article here.

NYU is Launching a Center for Psychedelic Medicine

Freethink, 07 March, 2021

NYU’s Langone Health joins the research renaissance.

Read more

Study Reveals More People are Using Psychedelics to Self-Treat Mental Health

Vice, 05 March, 2021

The use of psychedelic medicines as an underground self-treatment for mental health conditions is on the rise, according to the world’s largest drug survey, with thousands of people turning to substances like LSD, MDMA, psilocybin and ketamine to treat psychiatric illnesses and emotional distress.

Read more

Why the TGA should down-schedule psilocybin and MDMA

Honi Soit, 26 February, 2021

The Therapeutic Goods Administration should lead the way in destigmatising psychedelics.

Read more

Demand for illegal drugs in therapy

The Australian, 21 February, 2021

After an interim decision by the health regulator rejected an application to make psilocybin and MDMA more accessible for psychiatrists to treat mental illness, patients are increasingly turning to illicit treatments.

Read the PDF article here.

Read more

Proposed California Law Would Legalize Magic Mushrooms, MDMA, LSD, And Other Psychedelic Drugs

Forbes, 18 February, 2021

A proposal that would allow the possession, cultivation, use, and “sharing” of most psychedelic medicines in California was formally introduced in the state Legislature on Thursday.

Read more

2021 Time100 Next: Robin Carhart-Harris

Time, 17 February, 2021

Can psychedelic drugs treat depression? That’s the promise of findings from Robin Carhart-Harris, whose research is advancing a once fringe idea.

Read more

Young people’s despair over coronavirus deepens as crisis drags on

SMH, 15 February, 2021

With curfews, closures and lockdowns in European countries set to drag into the northern spring or even the summer, mental health professionals are growing increasingly alarmed about the deteriorating mental state of young people, who they say have been among the most badly affected by a world with a foreshortened sense of the future.

Read more

Young people’s despair over coronavirus deepens as crisis drags on

SMH, 15 February, 2021

With curfews, closures and lockdowns in European countries set to drag into the northern spring or even the summer, mental health professionals are growing increasingly alarmed about the deteriorating mental state of young people, who they say have been among the most badly affected by a world with a foreshortened sense of the future.

Read more

Trips out: regulator says no to ‘shrooms as treatment for mental illness

MSN, 10 February, 2021

In an interim decision published last week, the regulator refused to reschedule psilocybin and MDMA as controlled medical substances, a classification which would allow doctors to more easily prescribe them for treatment.

Read more

Psychedelic drug memo sparks uproar

The Australian, 09 February, 2021

The peak body for psychiatrists has been savaged by its own members for a “pitiful” clinical memorandum, which lay behind the health regulator’s preliminary decision not to reclassify psychedelic medicines.

Read the PDF article here.

Read more

Stroke victims to be given psychedelic drug DMT in groundbreaking study

Metro, 04 February, 2021

Psychedelic medicine DMT could help stroke victims recover by rewiring their brains faster, according to the first clinical trial of its kind.

Read more

Psychedelics as Antidepressants

Scientific American, 30 January, 2021

The treatments of the future may arise from a long-stigmatized class of medicines.

Read more

How ecstasy and psilocybin are shaking up psychiatry

Nature, 27 January, 2021

Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.

Read more

Ketamine to treat depression and addiction at UK’s first medical psychedelic psychotherapy clinic

iNews, 25 January, 2021

The medicine is to be used by Awakn Life Sciences when its centre opens in Bristol in March, explains its chief medical officer Dr Ben Sessa.

Read more

Unique magic mushroom microdosing study to begin in Australia

New Atlas, 20 January, 2021

A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics. The research promises to be the first exploration of naturalistic psilocybin microdosing in a lab-setting using a cutting-edge neuroimaging technique and a unique kind of trial protocol.

Read more

EXCLUSIVE: Florida Lawmaker Introducing Psilocybin Mushroom Legalization

Forbes, 15 January, 2021

A Florida state lawmaker plans to introduce as soon as next week a bill that would legalize psilocybin-assisted therapy in the state.

Read more

Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO

CNBC, 15 January, 2021

Headquartered in Berlin, ATAI is aiming to make psychedelic medicines that can be used to treat mental health disorders. Recognify, meanwhile, is specifically aiming to make a medicine that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.

Read more

Talking Music, Ceremony and Psychedelic-Assisted Therapy with Tania de Jong AM

Rune Soup, 13 January, 2021

Listen now

Mount Sinai Health System Launches Center for Psychedelic Research

Psychedelic Finance, 08 January, 2021

New York, Ny (January 07, 2021) The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multipronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.

Read more

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care

Globe News Wire, 08 January, 2021

Read more

Why Investors Are Psyched About Psychedelic Stocks

Visual Capitalist, 07 January, 2021

Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards.

Read more

Big pharma is about to tune in to the potential of psychedelics

Wired, 01 January, 2021

Mainstream mental-health care will embrace alternative active substances such as psilocybin.

Read more

Why Canada Could Be Next To Allow Psychedelic Therapy (And How It’s Already Changing Lives)

Forbes, 30 December, 2020

Now, as a handful of patients and more recently doctors and therapists have been granted exemptions to use psilocybin, the nation’s federal health agency is considering making changes to existing policies that could open the door to much more than magic mushrooms.

Read more

Psychedelic drug DMT to be trialled in UK to treat depression

The Guardian, 10 December, 2020

Exclusive: UK regulators give go-ahead for drug to be trialled ahead of possible treatment alongside psychotherapy.

Read more

New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression

UC Davis, 09 December, 2020

A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis. A paper describing the work is published Dec. 9 in Nature.

Read more

Health care professionals okayed to use magic mushrooms for training in psilocybin therapy

Now Toronto, 09 December, 2020

Psychologists, psychiatrists, social workers and nurses are among 17 health care professionals granted the exemption by Health Canada this week.

Read more

Can the active ingredient in magic mushrooms help treat anxiety? Researchers want to know.

The Age, 08 December, 2020

Australia is embarking on one of the world’s largest studies into the use of psychedelic drugs for mental health, with Melbourne researchers preparing to launch a world-first clinical trial investigating whether psilocybin – the active ingredient in “magic mushrooms” – can help treat people suffering severe persistent anxiety.

Read more

Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s

Parkinson's News Today, 04 December, 2020

Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease.

Read more

United Nations approves WHO recommendation to reschedule cannabis in historic vote

Marijuana Business Daily, 02 December, 2020

The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.

Read more

Psilocybin Treatment for Mental Health Gets Legal Framework

Scientific American, 01 December, 2020

Oregon became the first state to legalize therapeutic use of the drug, as new research affirms its benefits for treating depression.

Read more

'The war on drugs failed': California lawmaker will push to decriminalise psychedelics

The Guardian, 20 November, 2020

A California lawmaker has announced he will take on the arduous battle to decriminalize psychedelics in the state, citing Oregon, which voted to decriminalize hard drugs and legalize psilocybin, and the District of Columbia, which has decriminalized psychedelics, as inspiration.

Read more

Jewish psychedelics advocate working to turn drug into legal medicine

The Jerusalem Post, 20 November, 2020

In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value.

Read more

Psilocybin for Depression Study Approved and Funded by German Government

Psilocybin Alpha, 19 November, 2020

The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.

Read more

Canada Is Allowing People With Depression to Do Psychedelic Mushrooms

Vice World News, 17 November, 2020

The Canadian government is allowing patients who are not terminally ill to legally consume psychedelic mushrooms.

Read more

What the U.S. Military’s $27M investment in psychedelic drugs could mean for veterans with PTSD

The Dales Report, 11 November, 2020

The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.

Read more

Washington, DC, just decriminalized psychedelic plants. Here’s what happens next

Leafly, 04 November, 2020

Residents of the nation’s capital just took a step toward more liberal use of hallucinogens, in response to a groundswell of interest in new drugs for medical maladies.

Read more

Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’

CNBC, 04 November, 2020

Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.

Read more

Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020)

Ballotpedia, 03 November, 2020

Oregon Measure 109, the Psilocybin Program Initiative was on the ballot in Oregon as an initiated state statute on November 3, 2020. It was approved. Learn more here.

Read more

Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms

Forbes, 23 October, 2020

Read more

Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms

Forbes, 23 October, 2020

Read more

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

Plos One, 14 October, 2020

Read more

Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

MAPS, 14 October, 2020

Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $(USD)103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients.

Read more

What if a Pill Can Change Your Politics or Religious Beliefs?

Eddie Jacobs, Scientific American, 11 October, 2020

Read more

The New Yorker: Turn On, Tune In, Get Well

The New Yorker, 12 October, 2020

New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center.

Read more

PsyTech Hosts Live Investor Conference & Webinar October 27, 2020 and Closes Transaction with One of the Largest Psychedelic Conferences PsyTech.biz

Global News Wire, 25 September, 2020

PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Mind Medicine Australia Executive Director, Tania de Jong AM will be presenting alongside other distinguished speakers associated with Mind Medicine Australia including Professor David Nutt, Dr Rick Doblin, Professor Matthew W. Johnson, Dr Robin Carhart-Harris, Dr Adele Lafrance and Dr Reid Robison.

Read more

The Washington Post: Who Will Benefit From Psychedelic Medicine?

Washington Post, 21 September, 2020

Who Will Benefit From Psychedelic Medicine? These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Read more

Mind Medicine CEO Calls Compass IPO: A 'Clear Bellwether' For Psychedelic Space

Bezinga, 19 September, 2020

On Friday, UK-based mental health care company Compass Pathways NASDAQCMPS announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.

Read more

IntelGenx inks double deals to develop oral film psychedelics for psychiatric use

Fierce Pharma, 16 September, 2020

Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma industry.

Read more

UC Berkeley launches center for psychedelic science and education

Berkeleyside, 18 September, 2020

UC Berkeley launches center for psychedelic science and education With $1.25M in seed funding, the new center will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.

Read more

Usona Puts New Psilocybin Synthesis Method in the Public Domain

Ann Harrison, 15 September, 2020

The nonprofit Usona Institute has developed a new technique to synthesize kilograms of pharmaceutical grade psilocybin and placed this information in the public domain where it cannot be patented.

Read more

Psychedelics For CNS Disorders: Understanding The Opportunity

Ben Comer, 09 September, 2020

Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder.

Download the article here as a PDF.

Read more

Why Psychedelics Must be Legalized and Normalized: A Patients and Human Rights Argument

Eliott Edge, Medium, 11 October, 2018

Downlad the article here as a PDF.

Read more

Breaking the stigma: Psychedelic Drugs

Cannabis Life Network, 22 August, 2020

There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine). As they are, indeed, physiologically toxic and addictive. Psychedelics, on the other hand, have been mistaken to have the same, or even worse detrimental effects to one’s health.

Read more

Silicon Valley and Wall Street Elites Pour Money Into Psychedelic Research

The Wall Street Journal, 20 August, 2020

A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy using the key ingredient of the party drug Ecstasy to treat trauma patients.

Read more

Psychedelic Science in Post-Covid Psychiatry

DocWire News, 19 August, 2020

The medium to long term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19.

Read more

Eleusis sheds light on psychedelics that relieve asthma in rats with no mental effects

Fierce Biotech, 13 August, 2020

Psychedelic drugs like LSD have long been of interest in the medical community because of their anti-inflammatory properties. But efforts to transform them into therapeutics have been hampered by laws restricting the use of psychedelics, not to mention the stigma associated with them.

Read more

The first Canadian to legally consume psilocybin for medical purposes shares his experience

Regina Leader-Post, 21 August, 2020

Earlier this month, four Canadians received Section 56 exemption to the Controlled Drugs and Substances Act, allowing them to pursue psilocybin therapy for end-of-life distress.

Read more

Canada Will Let Terminally Ill Patients Use Psychedelic Mushrooms For End-Of-Life Care

CNN, 06 August, 2020

Four cancer patients in end-of-life care will be become the first people in decades to legally possess and consume psilocybin mushrooms in Canada after a landmark decision.

Read more

The Current Status of Psychedelics in Psychiatry

Dr David Nutt and Dr Robin Carhart-Harris, American Medical Association, 29 July, 2020

The Current Status of Psychedelics in Psychiatry

Download (47.3 KB)

Psilocybin Therapy for Addiction

60 Minutes USA, 21 July, 2020

Anderson Cooper sits down with Jon Kostakopoulos to discuss his experience as a clinical participant in an NYU psilocybin study treating alcohol use disorder.

Read more

Psilocybin & OCD: Can psychedelics treat obsessive compulsive disorder?

David E. Carpenter, Forbes, 12 May, 2020

Read more

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia: